SCHEMBL7138100

SCHEMBL7138100

[CH2]Oc1ccc(C(N)=O)cc1

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 18/20 0.67
PARP15 Q460N3 5/20 0.67
PARP4 Q9UKK3 2/20 0.67
PARP14 Q460N5 2/20 0.67
ALDH1A1 P00352 1/20 0.67
KMT2A Q03164 1/20 0.67
PARP16 Q8N5Y8 1/20 0.67
PARP11 Q9NR21 1/20 0.67
PARP2 Q9UGN5 4/20 0.61
CA1 P00915 1/20 0.61
CA2 P00918 1/20 0.61
PARP1 P09874 1/20 0.61
PARP3 Q9Y6F1 1/20 0.52
TNKS O95271 1/20 0.50
TNKS2 Q9H2K2 1/20 0.50
SENP8 Q96LD8 1/20 0.48
SENP6 Q9GZR1 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3137816 0.80 PARP10 (1.00) PARP10PARP15PARP4PARP14ALDH1A1
Terephthalamide SCHEMBL538997 0.79 PARP1 (0.63) PARP10PARP15PARP4PARP14ALDH1A1
Terephthalamide SCHEMBL15168441 0.79 PARP1 (0.63) PARP10PARP15PARP4PARP14ALDH1A1
Terephthalamide SCHEMBL23774 0.79 PARP1 (0.71) PARP10PARP15PARP4PARP14ALDH1A1
SCHEMBL17226019 0.78 PARP10 (0.70) PARP10PARP15PARP4PARP14ALDH1A1
SCHEMBL6168637 0.78 CA1 (0.60) PARP10PARP15ALDH1A1KMT2ACA1
SCHEMBL23235849 0.76 ST14 (0.67)
SCHEMBL17888032 0.76 PARP10 (0.67) PARP10PARP15PARP4PARP14ALDH1A1
SCHEMBL15259341 0.76 PARP10 (0.67) PARP10PARP15PARP4PARP14ALDH1A1
SCHEMBL20369059 0.76 PARP10 (0.67) PARP10PARP15PARP4PARP14ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030092634-A1 Novel compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. 2003-05-15 US claimed
US-6506733-B1 Which process comprises hydrogenating a compound of Formula 9: presence of a catalytic amount of 20% palladium hydroxide on carbon. AXYS PHARMACEUTICALS, INC. 2003-01-14 US claimed
EP-1159260-A1 NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2001-12-05 EP claimed
WO-2000055124-A2 NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2000-09-21 WO claimed
US-11944687-B2 Carbohydrate conjugate RNA agents and process for their preparation ALNYLAM PHARMACEUTICALS, INC. (US) 2024-04-02 US disclosed
EP-4253395-A2 PROCESSES FOR THE PREPARATION OF CARBOHYDRATE CONJUGATED RNA AGENTS Alnylam Pharmaceuticals, Inc. (US) 2023-10-04 EP disclosed
EP-2879718-B1 PROCESSES FOR THE PREPARATION OF CARBOHYDRATE CONJUGATED RNA AGENTS ALNYLAM PHARMACEUTICALS INC (US) 2023-06-07 EP disclosed
US-20190134206-A1 CARBOHYDRATE CONJUGATED RNA AGENTS AND PROCESS FOR THEIR PREPARATION ALNYLAM PHARMACEUTICALS, INC. 2019-05-09 US disclosed
US-10086081-B2 Carbohydrate conjugated RNA agents and process for their preparation ALNYLAM PHARMACEUTICALS, INC. (US) 2018-10-02 US disclosed
US-20150196655-A1 CARBOHYDRATE CONJUGATED RNA AGENTS AND PROCESS FOR THEIR PREPARATION BANK OF AMERICA, N.A. 2015-07-16 US disclosed
CN-104717982-A Carbohydrate conjugates and improved process for their preparation ALNYLAM PHARMACEUTICALS INC 2015-06-17 CN disclosed
EP-2879718-A1 CARBOHYDRATE CONJUGATED RNA AGENTS AND PROCESS FOR THEIR PREPARATION Alnylam Pharmaceuticals, Inc. (US) 2015-06-10 EP disclosed
WO-2000055124-A2 NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2000-09-21 WO disclosed
EP-0014566-B1 HALOGENATED BETA-LACTAM COMPOUNDS AND PROCESS FOR THEIR PREPARATION ELI LILLY AND COMPANY (US) 1983-05-25 EP disclosed
US-4357275-A Novel oxazolinoazetidinones and process therefor ELI LILLY AND COMPANY (US) 1982-11-02 US disclosed
US-4271305-A ANTIBIOTICS ELI LILLY AND COMPANY (US) 1981-06-02 US disclosed
EP-0022628-A1 Process for the preparation of oxazolinoazetidinones ELI LILLY AND COMPANY (US) 1981-01-21 EP disclosed
US-4243588-A CYCLIZING A 2-CHLOROAZETIDINONE WITH LEAD FLUORIDE IN DIMETHYL SULFOXIDE TO OBTAIN THE 4-OXA-2,6-DIAZABICYCLO(3.2.0)HEPTANE ELI LILLY AND COMPANY (US) 1981-01-06 US disclosed
US-4226986-A 7-ACYLAMINO-3-HYDROXY-3-CEPHEM COMPOUND, TRIARYL PHOSPHITE DIHALIDE ELI LILLY AND COMPANY (US) 1980-10-07 US disclosed
EP-0014566-A1 Halogenated beta-lactam compounds and process for their preparation ELI LILLY AND COMPANY (US) 1980-08-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10086081-B2 Carbohydrate conjugated RNA agents and process for their preparation RNASE1, IGF2BP1, IGF2BP2 PARP10 810/4885PARP15 1213/4885PARP4 866/4885
US-20190134206-A1 CARBOHYDRATE CONJUGATED RNA AGENTS AND PROCESS FOR THEIR PREPARATION RNASE1, IGF2BP1, IGF2BP2 PARP10 810/4885PARP15 1213/4885PARP4 866/4885
US-20030092634-A1 Novel compounds and compositions as protease inhibitors SERPINB1, HPN, CTRL PARP10 1469/4885PARP15 876/4885PARP4 1789/4885
US-20150196655-A1 CARBOHYDRATE CONJUGATED RNA AGENTS AND PROCESS FOR THEIR PREPARATION RNASE1, IGF2BP1, IGF2BP2 PARP10 810/4885PARP15 1213/4885PARP4 866/4885
US-11944687-B2 Carbohydrate conjugate RNA agents and process for their preparation RNASE1, IGF2BP1, IGF2BP2 PARP10 890/4885PARP15 1337/4885PARP4 967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.